Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents

Cheer, Susan M., Figgitt, David P. · 2001 · Paediatric Drugs

Abstract

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day. However, steady-state plasma fluvoxamine [corrected] concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents; thus, the maximum fluvoxamine dosage recommended for children is 200 mg/day. Fluvoxamine (50 to 300 mg/day) for 8 to 16 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) [measured across multiple assessment scales] compared with placebo in a well controlled trial in paediatric patients (n = 120) or from baseline in noncomparative trials in adolescent (n = 20) or paediatric (n = 16) patients. Improvements with fluvoxamine (up to 200 mg/day) were observed for up to 1 year in 98 patients with OCD in a noncomparative trial. The drug (up to 250 or 300 mg/day) also improved symptoms of anxiety compared with placebo in an 8-week well controlled trial in 128 paediatric patients with social phobia, separation anxiety disorder or generalised anxiety disorder (GAD). Fluvoxamine (50 to 300 mg/day) appears to be well tolerated in paediatric patients, with most adverse events with the drug (except abdominal discomfort, which occurred more often in patients receiving fluvoxamine) occurring with a similar incidence to those with placebo. The most common adverse events involved the central nervous system or gastrointestinal system. Most adverse events reported by paediatric patients with OCD were similar to those reported by adults. In conclusion, fluvoxamine is generally well tolerated and has demonstrated short-term efficacy compared with placebo in the treatment of OCD, and social phobia, separation anxiety disorder or GAD in well controlled trials in paediatric patients. Reductions in symptoms of anxiety with fluvoxamine have been observed for up to 1 year in children and adolescents with OCD. However, there are currently no comparative trials of fluvoxamine with other pharmacological agents. In the absence of such trials, current consensus opinion recommends that when pharmacotherapy is indicated, fluvoxamine, like other SSRIs, can be used as first-line treatment for anxiety disorders, particularly OCD, in paediatric patients. However, direct comparisons are required to assess the relative efficacy and tolerability of pharmacological agents in order to make firm recommendations for the treatment of anxiety disorders in this patient group.

Overview

Integrity signals

Registry

Crossref · 10.2165/00128072-200103100-00004

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 96 references

Research works printed but not linked: 13

  1. Benfield, 1986, Drugs, 32, 482
  2. Richelson, 1984, J Pharmacol Exp Ther, 230, 94
  3. Horton, 1994, Can J Physiol Pharmacol, 72, 442
  4. Laird, 1993, J Clin Psychiatry, 54, 224
  5. ZumBrunnen, 2001, Clin Pharmacol Ther, 69, 82
  6. Vandel, 1997, Therapie, 52, 74
  7. Xu, 1996, Chung-Kuo Yao Li Hsueh Pao [Acta Pharmacol Sin], 17, 399
  8. Spina, 1993, Int J Clin Pharmacol Res, 13, 167
  9. DeVane, 1997, Am J Psychiatry, 154, 1317
  10. van den Brekel, 1994, Can Med Assoc J, 151, 1289
  11. Macher, 1999, Hamberg, II, 108
  12. 1997, J Clin Psychiatry, 58, 1
  13. DeVane, 1996, J Clin Psychiatry, 57, 55

Cited by

See all 15

Metadata

Authors
Cheer, S. M., & Figgitt, D. P.
Corresponding author
Cheer, Susan M.
Venue
Paediatric Drugs
Published
2001
Volume
3
Issue
10
Pages
763-781
ISSN
1174-5878 (ISSN-L)
OpenAlex
W2041245802
Cited by
15
References
96
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2016: 2 · 2013: 1
FWCI
0.98
Type
journal article
Language
en
Open access
closed
Locations
  • Pediatric Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
fluvoxamine, selective serotonin reuptake inhibitors, obsessive-compulsive disorder, social anxiety disorder, separation anxiety disorder, generalized anxiety disorder, plasma drug concentration, adverse events, drug tolerability, first-line therapy, dosing recommendations, long-term treatment outcomes, placebo comparison, central nervous system adverse events
MeSH terms
Adolescent, Anxiety, Separation, Child, Drug Interactions, Humans, Obsessive-Compulsive Disorder, Phobic Disorders, Anti-Anxiety Agents, Fluvoxamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents. https://app.cochat.ai/papers/10.2165/00128072-200103100-00004
The paper
Cheer, S. M., & Figgitt, D. P. (2001). Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents. Paediatric Drugs. https://doi.org/10.2165/00128072-200103100-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.